Division of NeoGenomics Inc.
Latest From Genoptix Inc.
A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.
Now backed by Roche, can Foundation Medicine continue to innovate in the delivery of molecular information in oncology and outpace the twin threats posed by the commoditization and regulation of genomic data?
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Laboratory Testing Services
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- DNA Dynamics Inc.
- Genoptix Medical Laboratory
- North America
- Parent & Subsidiaries
- NeoGenomics Inc.
- Senior Management
Joseph M Limber, Pres. & CEO
Mark E Spring, CFO
Derek D Lyle, MD, CMO & Medical Dir.
Juan Estruch, Head, Corp. Dev.
- Contact Info
Phone: (760) 268-6200
2131 Faraday Ave.
Carlsbad, CA 92008
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.